Kidney Transplant Nightmare: Parasite From Donor Nearly Costs Man His Life
As per the case report in this week's issue of the New England Journal of Medicine, the patient's oxygen levels in the blood had started to fall and the lungs were filled with fluid. Doctors inserted a feeding tube, but the oxygen levels and blood pressure kept falling. Eventually, he was admitted to the ICU.
With the patient's condition deteriorating, the doctors at Mass General started the process of elimination to figure out the root cause of the problem. The wife was contacted for more information, while the regional organ-procurement organisation that provided the kidney was also called up for more insights.
In the meantime, the lab reports suggested that the patient had some sort of infection. However, since the patient was a recent kidney recipient and on a variety of immunosuppressive drugs, the list of infectious possibilities was "extensive".
Dr Camille Kotton, Clinical Director of the hospital's Transplant and Immunocompromised Host Infectious Diseases division, went through the patient's history and ruled out herpesviruses and cytomegalovirus, as some of the medications would have proactively prevented these infections, according to a report in Ars Technia.
The investigation
While analysing the patient, Dr Kotton noticed that he had elevated levels of eosinophils, white blood cells that can increase for various reasons, including parasitic infections. He also had a reddish-purple rash over his abdomen, which prompted Dr Kotton to suspect a parasitic infection.
Strongyloides, a parasitic roundworm that infects the gastrointestinal tract, was suspected as the cause of the patient's problems. To test the hypothesis, Dr Kotton called the organ-procurement organisation and found that the donor was from the Caribbean, where Strongyloides are present.
The donor's blood was not tested for the infection before the transplant, but blood samples showed antibodies against the parasite. The transplant patient's pre-transplant blood samples, on the other hand, were negative.
After the confirmation, doctors conducted the tests, which revealed that the patient had worm larvae in the lungs and stool. To treat such a widespread infection, they had to use a deworming drug called ivermectin, which is only approved by the Food and Drug Administration for oral formulations in humans.
After receiving special approvals, the ivermectin was delivered subcutaneously to the patient. While the patient recovered, doctors received a message that the person who received the donor's other kidney was also critically ill.
The doctors shared notes, and both patients managed to make a full recovery. The case prompted the United Network for Organ Sharing to update its policy to recommend universal screening for Strongyloides.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
Ice cream bars recalled in the US: Listeria alert announced in 23 states, full list of affected regions
No matter how much the summer heat prompts you, it would be better to freeze the ice cream cravings for now. Recently, Listeria has prompted the recall of more than 100,000 cases of ice cream bars in 23 states across the United States, according to the U.S. Tired of too many ads? go ad free now Food and Drug Administration. According to the Centers for Disease Control and Prevention (CDC), approximately 1,600 people in the United States are diagnosed with Listeria annually. The illness, caused by the Listeria monocytogenes bacteria, is the third leading cause of death from foodborne illness, with about 260 deaths per year. Now it has contaminated 10 different varieties of Rich's Ice Cream, prompting a voluntary recall by the Florida-based brand on June 27. The recall was made public in a July 17 FDA enforcement report and continues now. Rich's Ice Cream recalled: Flavours to avoid Image credits: Getty Images Each product was sold in cases of 96 individually wrapped bars. The recalled lot numbers range from 24351 to 25156, based on Julian calendar dating. If you've recently bought one of these bars at home, check the packaging for the codes to see if it is recalled. These are flavours of ice cream bars contaminated with Listeria, you should avoid buying: Chocolate Crunch Cake Bar Strawberry Shortcake Bar Rich Bar Crumbled Cookie Bar Orange Cream Bar Fudge Frenzy Bar Cotton Candy Twirl Bar Savagely Sour Blue Raspberry Bar Savagely Sour Cherry Bar Cool Watermelon Bar Rich's Ice Cream recalled: List of affected regions Image credits: Getty Images The ice cream bars were shipped to 23 states across the US. These include: Georgia Nassau Bahamas Alabama Arizona California Florida Illinois Iowa Louisiana Massachusetts Montana Nebraska Nevada New Jersey New York Ohio Oklahoma Oregon Pennsylvania South Carolina Tennessee Texas Virginia Wisconsin What are the concerns with Listeria? Listeria is a foodborne illness caused by the food getting contaminated with the Listeria monocytogenes bacteria. It typically affects pregnant women, older adults, children and people with weakened immune systems. Symptoms of infection include fever, muscle ache, headache, diarrhea and more. If you have eaten any listeria-contaminated food, visit a medical professional immediately.
Mint
3 days ago
- Mint
Mint Explainer: Can AI diagnose you better than a doctor?
Few sectors are witnessing AI's disruptive power as dramatically as healthcare. Trained on millions of historical patient records, advanced AI models are now matching—and in some cases surpassing—human expertise. With real-time analysis across medical histories, imaging, and genetic profiles, AI transforms clinical complexity into diagnostic clarity. AI spots patterns even seasoned physicians might overlook. Earlier this month, Microsoft unveiled a platform–Microsoft AI Diagnostic Orchestrator (MAI-DxO)—that can diagnose medical cases with an accuracy rate of up to 85.5%, far exceeding the 20% accuracy of experienced physicians under the same conditions. Mint explains the role and impact of AI in healthcare and diagnostics. Does Microsoft's MAI-DxO improve diagnostic accuracy? MAI-DxO leverages vast datasets, advanced probabilistic reasoning, and continuous learning from clinical cases to surpass human diagnostic accuracy. Unlike doctors who rely on experience and pattern recognition, MAI-DxO evaluates multiple variables simultaneously—lab results, symptoms, imaging—and predicts outcomes. MAI‑DxO was tested on 304 real-world clinical scenarios sourced from the New England Journal of Medicine. In these cases, MAI‑DxO achieved an accuracy rate of 85.5%, surpassing the average 20% success rate of 21 experienced physicians from the UK and the US. Instead of relying on a single model, MAI-DxO coordinates multiple large language models (LLMs) that interact like a team of doctors, reviewing, challenging, and refining each other's suggestions before settling on a final diagnosis. Microsoft has emphasised that the tool is not designed to replace doctors, but to work alongside them. What medical datasets does MAI-DxO use? MAI-DxO is trained on anonymised patient records, peer-reviewed literature, medical guidelines and global clinical datasets from hospitals and research institutions. Its database spans symptoms, biomarkers, comorbidities, and disease trajectories across demographics, allowing it to contextualize findings in real-world scenarios. So if a patient suddenly feels numbness on her left side, it could indicate stroke, nerve damage, heart problem or some other issue. Doctors will wait for test results (blood and scans) to diagnose the problem, while the AI platform will interpret it faster, helping the doctor make quicker decisions. MAI-DXO's strength lies in its ability to absorb medical nuance across specialties—mirroring the cumulative expertise of several doctors and researchers. Will AI replace doctors? AI will not replace but complement doctors and other health professionals. They need to navigate ambiguity and build trust with patients. Clinical roles will evolve with AI, giving medical staff the ability to automate routine tasks, identify diseases earlier, personalize treatment plans, and potentially prevent some diseases altogether. For consumers, they will provide better tools for self-management and shared decision-making. These will be particularly helpful in remote areas where there's a shortage of doctors. MAI-DxO operates on statistical inference rather than intuition. It learns to recognise patterns and contextual subtleties from data, simulating judgment. While human intuition draws on tacit knowledge—emotion, empathy, gut feel—AI taps structured data and outcome probabilities. Platforms like MAI-DxO can augment decision-making. These are especially useful when doctors second-guess themselves—making MAI-DxO an ally, not a rival. What risks do AI-driven diagnostics pose for patient care? Key risks include overreliance, bias from skewed training data, and lack of transparency in AI reasoning. If doctors defer judgment too easily, subtle clinical clues could be overlooked. Additionally, AI platforms recommendations may vary based on demographics or comorbidities not well represented in its training data, potentially exacerbating health disparities. For instance, if they are trained only on American or European patient data, they might overlook or misinterpret common conditions among patients in South Asia, say tuberculosis (TB) or type 2 diabetes or complications caused by chewing tobacco. There's also the risk of false positives and patient anxiety. Most critically, AI tools must be accountable — patients need clarity on how diagnoses are made. The challenge lies in integrating AI without ignoring the human touch in care. What are the regulatory frameworks for AI deployment in hospitals? In India, every AI tool must be approved by the Delhi-based Central Drugs Standard Control Organisation (CDSCO)— equivalent to the US Food and Drug Administration (FDA). Globally, regulatory bodies like the FDA (US), European Medicines Agency (EMA-Europe) are developing guidelines for AI in medicine. Back home, AI platforms need clearance as a software as a medical device (SaMD), requiring evidence of clinical safety, efficacy, and data privacy compliance. What is the role of AI in the future of medicine? Current developments position them as early warning systems, helping doctors rather than making final decisions. According to the World Economic Forum 4.5 billion people are currently without access to essential healthcare services and a health worker shortage of 11 million is expected by 2030. AI has the potential to help bridge that gap. AI can also assist paramedics in situations where a patient is being transferred via an ambulance. AI models trained on factors such as a patient's mobility, pulse and blood oxygen levels, chest pain, etc., can relay information to doctors, helping them make decisions faster. AI can detect early signs in an individual that are likely to result in diseases like Alzheimer's, heart disease, kidney disease, and so on. This could help doctors suggest preventive action. Can MAI-DxO evolve into a real-time medical assistant across specialties? At present, MAI-DxO is a demonstration of AI capability and research. With real-time access to patient records, labs, and imaging, MAI-DxO could become an assistant, offering diagnostic suggestions, tracking progress, and alerting doctors to anomalies as they emerge. Integrated into electronic health systems, it could support rounds, triage, and even remote consultations. Much like AI embedded medical devices (ultrasound devices, bedside X-ray machines) are now being used in some hospitals, including Max healthcare, to interpret scans and assist doctors. The key lies in continual updates, feedback loops and building trust.
Time of India
4 days ago
- Time of India
Poor Europeans live longer than rich Americans, study reveals stark contrast
It's a common perception that a wealthy person, with comfort, stability, and access to top-tier healthcare, is more likely to live a longer and healthier life. But a new study challenges this belief and reestablishes an old saying: money isn't everything, at least not when it comes to health and longevity. Published in the New England Journal of Medicine, the study tracked nearly 74,000 individuals aged 50 to 85 across the US and 16 European countries from 2010 to 2022. Surprisingly, some of the poorest Europeans were found to outlive even the wealthiest Americans, revealing deep disparities tied to national healthcare systems and social structures. Europe vs. US: Wealth doesn't guarantee longevity Researchers divided Europe into three regions—northern and western, southern, and eastern—comparing survival rates to those in the United States. The US had the highest overall death rate at 6.5 per 1,000 people, while northern and western Europe had a much lower rate of 2.9. Even more telling, wealthy Americans had lower survival rates than everyone in northern and western Europe and were only on par with the poorest in those regions. This pattern persisted across multiple metrics. The poorest Americans died younger than their European counterparts, and the survival gap between America's rich and poor was the widest of any nation studied. According to researchers, factors like income inequality, limited access to healthcare, and weaker social support structures in the US help explain this disturbing trend. The role of welfare systems and social support Experts say Europe's stronger welfare policies likely play a major role in these outcomes. Countries like the Netherlands, France, and Germany provide broader access to healthcare, affordable housing, and public support for aging populations. Dr. Martin McKee, a professor of European public health, noted that robust social safety nets benefit not just the poor, but the middle class as well. Europe's universal healthcare systems, along with preventive care programs, income support, elder care, and housing assistance, create a protective framework that sustains public health across all socioeconomic groups. These policies don't only improve outcomes for those at the bottom—they raise the baseline for everyone. In contrast, the US approach—heavily reliant on employer-based insurance, private healthcare, and minimal government intervention—excludes millions and creates gaps even among those with stable incomes. The study controlled for major risk factors such as gender, education, smoking habits, and chronic illnesses, which strengthens its conclusion that national policy—not just personal behavior—plays a pivotal role in longevity. However, it did not account for the influence of racial disparities or the ultra-wealthy 1%, which researchers say could further widen the inequality picture. Still, the core message remains stark: a society's collective investment in healthcare and social support directly impacts how long and well its people live.
